INMB Stock Analysis: Buy, Sell, or Hold?
INMB - INmune Bio Inc. Common stock
$1.49
-0.06 (-3.87%)
▼
5d:
+10.37%
30d:
+2.76%
90d:
+6.43%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
INMB is down 9.7% this week, but smart money is accumulating calls. Top strike: $1.5 2026-06-18 with 753 OI. Call ratio: 100% View Scanner →
Strength: 9.9/10
Get Alerted When INMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called INMB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INMB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INMB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INMB is currently trading at $1.49, which is considered extended relative to its 30-day fair value range of $1.29 to $1.51.
Technical Outlook: Technically, INMB is in a strong downtrend. Immediate support is located at $1.31, while resistance sits at $1.79. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: INMB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+369.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INMB is in a strong downtrend. Immediate support is located at $1.31, while resistance sits at $1.79. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: INMB has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+369.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.29 -
$1.51
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 369.8% below Wall St target ($7.00)
Trading Range Analysis
30-Day Trading Range
$1.29 -
$1.51
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.31
Resistance Level
$1.79
Current Trend
Strong Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.84
Wall Street Target
$7.00
(+369.8%)
Revenue Growth (YoY)
257.1%
Share & Embed Analysis
Last updated: May 18, 2026 7:43 PM ET
Data refreshes hourly during market hours. Next update: 8:43 PM
Data refreshes hourly during market hours. Next update: 8:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 50 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 56 HOLD |
